April 9 Quick Takes: BMS tops off CAR T patent win; plus approval for Braftovi plus Erbitux, Merck, BMS, Liquidia, Circassia-AZ, Bridge

Award swells to $1.2B, plus royalties, in Kite CAR T suit
Bristol Myers Squibb Co. (NYSE:BMY) and Memorial Sloan Kettering Cancer Center will receive at least $1.2 billion from Gilead Sciences Inc. (NASDAQ:GILD) after a federal judge awarded the pair an additional $420 million. In December, a jury in the U.S. District Court

Read the full 525 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE